Surrogate end points for overall survival in trials of PD-(L)1 inhibitors for urinary cancers: a systematic review.

about

Surrogate end points for overall survival in trials of PD-(L)1 inhibitors for urinary cancers: a systematic review.

Item

http://www.wikidata.org/entity/Q47278600

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Surrogate end points for overall survival in trials of PD-

@nl

Surrogate end points for overa ...... cancers: a systematic review.

@en

type

Item

label

Surrogate end points for overall survival in trials of PD-

@nl

Surrogate end points for overa ...... cancers: a systematic review.

@en

prefLabel

Surrogate end points for overall survival in trials of PD-

@nl

Surrogate end points for overa ...... cancers: a systematic review.

@en

P1476

Surrogate end points for overa ...... cancers: a systematic review.

@en

P2093

Omar Abdel-Rahman

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer immunotherapy: moving beyond current vaccines

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial

Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data.

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

P304

139-148

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.2217/IMT-2017-0115

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29260622

http://www.w3.org/2001/XMLSchema#string